Antengene’s XPOVIO received regulatory approval in Hong Kong for Relapsed and/or Refractory Multiple Myeloma

The FDA accepts sNDA for BeiGene’s BRUKINSA in R/R Follicular Lymphoma

LianBio entered into a clinical supply agreement with AstraZeneca for BBP-398 in EGGFR Mu NSCLC

China’s NMPA approved Daiichi Sankyo and AstraZeneca’s ENHERTU in HER2-low metastatic Breast Cancer

Roche’s COLUMVI gets EC’s nod for relapsed/refractory diffuse large B-cell lymphoma (DLBCL)